Bicara Therapeutics Inc. Common Stock (BCAX)

Bicara Therapeutics Inc. Common Stock (BCAX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $1.2B; returns 1 day -3.1%, 1 week +1.7%, 1 year +0.9%.

Bicara Therapeutics Inc. (BCAX) is a clinical-stage biopharmaceutical company specializing in the development of bifunctional antibody therapies designed to modulate the tumor microenvironment. The company's lead product candidate is ficerafusp alfa (formerly BCA101), a first-in-class bifunctional antibody that combines an EGFR-directed monoclonal antibody with a TGF-β trap.

Groups BCAX belongs to

• Biotechnology
• Clinical Stage Biotech
• Oncology
• Biopharmaceutical
• Antibody Therapeutics
• Monoclonal Antibodies
• Clinical Stage
• Cancer Therapeutics
• Healthcare
• Immunotherapy
• Life Sciences

BCAX financial model: income statement, cash flow and balance sheet